Table 4.
CR in de novo AML | CR in secondary AML | ||||||
---|---|---|---|---|---|---|---|
Haplotype group | Total N | ||||||
N1* | OR/HR | CI | N1* | OR/HR | CI | ||
AA/AC/BB/BC/CC | 151 | 62 | 1.00 | – | 14 | 1.00 | – |
DA/DB/DC/DD | 122 | 58 | 1.08 | 0.58–2.02 | 12 | 1.92 | 0.64–5.75 |
Total | 273 | 120 | 26 | ||||
AA** | 105 | 43 | 1.00 | – | 5† | 1.00 | – |
DA | 18 | 8 | 1.25 | 0.34–4.64 | 2† | 10.55 | 0.45–287.48 |
DC | 85 | 41 | 1.42 | 0.68–2.45 | 9†† | 7.73 | 1.36–59.24 |
Other | 65 | 28 | 1.79 | 0.75–4.26 | 10†† | 5.05 | 0.98–34.50 |
AA (‘0’ variant alleles) | 105 | 43 | 1.00 | – | 5† | 1.00 | – |
AC/DA (1 variant allele) | 29 | 12 | 1.13 | 0.39–3.29 | 2† | 4.32 | 0.24–72.29 |
CC/DD/DC (2 variant alleles) | 89 | 43 | 1.52 | 0.73–3.13 | 9†† | 6.35 | 1.14–47.16 |
BC/DB (3 variant alleles) | 26 | 12 | 1.28 | 0.34–4.78 | 3† | 2.99 | 0.31–28.12 |
BB (4 variant alleles) | 24 | 10 | 2.54 | 0.70–9.21 | 7†† | 18 31 | 2 08–283 57 |
OS in de novo AML | OS in secondary AML | ||||||
AA/AC/BB/BC/CC | 151 | 77 | 1.00 | – | 41 | 1.00 | – |
DA/DB/DC/DD | 122 | 70 | 1.06 | 0.77–1.47 | 24 | 0.70 | 0.41–1.21 |
Total | 273 | 147 | 65 | ||||
AA** | 105 | 55 | 1.00 | – | 25 | 1.00 | – |
DA | 18 | 7 | 0.69 | 0.31–1.52 | 5 | 0.62 | 0.21–1.83 |
DC | 85 | 54 | 1.15 | 0.79–1.68 | 14 | 0.41 | 0.20–0.83 |
Other | 65 | 31 | 1.33 | 0.79–2.23 | 21 | 0.61 | 0.30–1.23 |
AA (‘0’ variant alleles) | 105 | 55 | 1.00 | – | 25 | 1.00 | – |
AC/DA (1 variant allele) | 29 | 14 | 0.94 | 0.52–1.69 | 8 | 0.60 | 0.25–1.45 |
CC/DD/DC (2 variant alleles) | 89 | 55 | 1.13 | 0.78–1.65 | 16 | 0.44 | 0.23–0.87 |
BC/DB (3 variant alleles) | 26 | 12 | 1.40 | 0.73–2.68 | 8 | 0.58 | 0.25–1.35 |
BB (4 variant alleles) | 24 | 11 | 1.09 | 0.56–2.11 | 8 | 0.31 | 0.14–0.73 |
N1=number of CR/deaths with certain haplotype
models adjusted for age, cytogenetic group, AML onset (if not stratified), HSCT, WBC count
Exact OR and CR are calculated
p-value=0.02 (DC), 0.05 (Other), 0.03 (CC/DD/DC), 0.004 (BB) accordingly